EUVIMEDEUVIMED entdecken
Crossref

Deoxynojirimycin derivatives as potent α-glucosidase inhibitors: in silico ADMET evaluation, molecular dynamics and in vitro validation studies

Fariya Khan, Suhail Ahmad, Khwaja Osama, Alvina Farooqui, Ajay Kumar, Salman Akhtar

Molecular Diversity · 2025

DOI: 10.1007/s11030-025-11307-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Diversity, 2025. Verfasst von Fariya Khan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioengineering, Integral University, Lucknow, India. Hauptthemen laut MEDLINE: Glycoside Hydrolase Inhibitors, 1-Deoxynojirimycin, Molecular Dynamics Simulation, alpha-Glucosidases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

α-Glucosidase plays a critical role in digesting carbohydrates, leading to an increase in postprandial glucose levels, which contributes to the development and progression of diabetes. By inhibiting this enzyme, it is possible to manage postprandial hyperglycemia, thereby reducing the risk of developing or exacerbating diabetes. The primary aim of our study was to identify and evaluate potential α-glucosidase inhibitors from a series of deoxynojirimycin derivatives, using a combination of binding affinity analysis, simulation studies, and in vitro experiments. 371 deoxynojirimycin analogs were screened based on their compliance with Lipinski's Rule of Five and favorable absorption, distribution, metabolism, excretion, and toxicity (ADMET) parameters. Among these, compound MG257 (C10H21NO4) stood out due to its strong binding interactions with the active site residues of α-glucosidase, as demonstrated through virtual screening and docking studies. In our in vitro analysis, MG257 (C10H21NO4) demonstrated a notably potent α-glucosidase inhibitory activity with an IC50 value of 0.44 ± 0.18 µM, surpassing the standard inhibitor miglitol, which exhibited an IC₅₀ of 0.64 ± 0.26 µM. Furthermore, molecular dynamics simulations conducted over 100 ns revealed that MG257 maintained excellent stability, further supporting its potential as a reliable inhibitor. Enzyme kinetics studies also confirmed that MG257 inhibits α-glucosidase competitively, reinforcing the findings from the molecular docking and simulation data. These comprehensive results, combining in silico and in vitro approaches, underscore the drug-likeness of MG257 and its promising pharmacokinetic profile. In conclusion, our findings suggest that MG257 (C10H21NO4) is a potent α-glucosidase inhibitor with significant potential as a novel therapeutic agent for the management of Type 2 diabetes, warranting further research and development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glycoside Hydrolase Inhibitors1-DeoxynojirimycinMolecular Dynamics Simulationalpha-GlucosidasesMolecular Docking SimulationHumansKinetics

Stichwörter der Autor:innen

DeoxynojirimycinHyperglycemiaMiglitolMolecular dynamicsType 2 diabetesVirtual screeningα-Glucosidase

Substanzen

Glycoside Hydrolase Inhibitors1-Deoxynojirimycinalpha-Glucosidases

Autor:innen und Institutionen

  • Department of Bioengineering, Integral University, Lucknow, India.
  • Department of Biotechnology, Faculty of Engineering and Technology, Rama University, Kanpur, India.
  • Department of Bioengineering, Integral University, Lucknow, India. salmanakhtar18@gmail.com.
  • Novel Global Community Educational Foundation, Peterlee Place, Hebersham, NSW, 2770, Australia. salmanakhtar18@gmail.com.

Zitieren

APA

Khan, F., Ahmad, S., Osama, K., Farooqui, A., Kumar, A., & Akhtar, S. (2025). Deoxynojirimycin derivatives as potent α-glucosidase inhibitors: in silico ADMET evaluation, molecular dynamics and in vitro validation studies. Molecular Diversity. https://doi.org/10.1007/s11030-025-11307-2

Vancouver

Khan F, Ahmad S, Osama K, Farooqui A, Kumar A, Akhtar S. Deoxynojirimycin derivatives as potent α-glucosidase inhibitors: in silico ADMET evaluation, molecular dynamics and in vitro validation studies. Molecular Diversity. 2025. doi:10.1007/s11030-025-11307-2

BibTeX
@article{Khan2025,
  author = {Khan, Fariya and Ahmad, Suhail and Osama, Khwaja and Farooqui, Alvina and Kumar, Ajay and Akhtar, Salman},
  title = {Deoxynojirimycin derivatives as potent α-glucosidase inhibitors: in silico ADMET evaluation, molecular dynamics and in vitro validation studies},
  journal = {Molecular Diversity},
  year = {2025},
  doi = {10.1007/s11030-025-11307-2}
}
Kostenlos starten →